• Introduction to Brain Tumors
    • Gliomas

      Gliomas are the most common malignant primary brain tumors with a poor prognosis. The World Health Organization (WHO) classification of central nervous system tumors divides gliomas into grades I-IV. Grade Ⅳ glioblastoma has the highest incidence, accounting for about 46% of gliomas. Conventional treatment options, including surgical chemoradiotherapy, have not been optimal, so new therapeutic strategies such as targeted therapy immunotherapy are urgently needed.

      Overview:
      Product Features:
      Suitable Patient Profile:
    • Pituitary tumors

      Pituitary tumors are one of the most common intracranial neuroendocrine tumors, accounting for 10%-15% of central nervous system tumors. The vast majority of pituitary tumors are benign tumors, and only about 2-5% are pituitary cancers. Surgery is the main treatment, supplemented by radiotherapy and drug treatment.

      Overview:
      Product Features:
      Suitable Patient Profile:
    • Meningiomas

      Meningiomas are one of the most common central nervous system tumors. Most meningiomas are benign tumors and only about 10% of all meningiomas are malignant. Surgery is the main treatment, supplemented by radiotherapy and drug treatment.

      Overview:
      Product Features:
      Suitable Patient Profile:
    • Medulloblastomas

      Medulloblastomas are common embryonic malignant brain tumors in children's central nervous system, accounting for 25% of intracranial tumors in children and less in adult patients. The main treatment regimen is postoperative stratified treatment based on risk factors (total brain spinal radiotherapy and adjuvant chemotherapy). Risk stratification and precise treatment based on molecular subtypes are the current research hotspots and directions.

      Overview:
      Product Features:
      Suitable Patient Profile:
  • Significance of Gene Testing in Brain Tumors

    Tests can be used for classification diagnosis, prognosis assessment and risk assessment to assist in the development of routine chemoradiotherapy treatment programs, screening appropriate targeted drugs and providing genetic risk warnings to patients. Specialized brain tumor panel offers important references in tailoring individualized service for those undergoing the screening. Furthermore, it also enhances research into areas pertaining to mechanisms of drug tolerance, drug sensitive sites, tumor development mechanisms and prospective study on oncogene drivers.

    • Genetron in Brain Tumors Testing

      The discoverer of glioma-driven genes

      The first domestic CFDA-certified brain tumor kit

      NCCN  Guidelines (Chinese edition) compiler and promoter

      A million-level Chinese brain tumor molecular variation database

      A number of brain tumor diagnosis and treatment milestone research achievements

      Overview:
      Product Features:

      Tests can be used for classification diagnosis, prognosis assessment and risk assessment to assist in the development of routine chemoradiotherapy treatment programs, screening appropriate targeted drugs and providing genetic risk warnings to patients. Specialized brain tumor panel offers important references in tailoring individualized service for those undergoing the screening. Furthermore, it also enhances research into areas pertaining to mechanisms of drug tolerance, drug sensitive sites, tumor development mechanisms and prospective study on oncogene drivers.

      Suitable Patient Profile:
  • Genetron’s Genomic Testing Service for Brain Tumor
    • Onco PanScan™️ (tissue/blood)

      Overview:

      Combined with Genetron’s universal tumor database, the solid tumor 825 genes testing covers an updated version of the WHO, NCCN, ESMO and other authoritative guidelines and expert consensus recommended test genes. Based on the high-throughput, highly sensitive NGS platform and 'hybrid capture' technology, solid tumor 825 genes testing can provide multi-dimensional immunotherapy related biomarker detection (TMB, MSI, PD-L1, immune efficacy related gene variation), so as to guide the individualized diagnosis and treatment of tumor patients more accurately. It also provides more comprehensive reference information for researchers

      Product Features:

      1. Focus on 238 tumor drugs, covering 12 classic tumor signaling pathways, 45 chemotherapy drug related sites, 90 immunotherapy related genes, 149 tumor genetic susceptibility genes
      2. Comprehensive and real-time dynamic monitoring of recurrent metastasis and the mechanism of molecular change in drug-resistant patients, to achieve the full course of cancer monitoring and management
      3. Multi-dimensional immunotherapy assessment

      Suitable Patient Profile:

      Tumor patients seeking more opportunities for targeted drugs or immunotherapy

    • 68 genes brain tumor testing (tissue/blood)

      Overview:

      The most cost-effective brain tumor product to date

      Product Features:

      The only product targeted at brain tumors, containing 68 genes, covering prognostic typing and targeted drug indications

      Suitable Patient Profile:

      Patients with brain tumor

    • Medulloblastoma molecular classification testing

      Overview:

      The pathologic classification must be checked for patients with medulloblastoma

      Product Features:

      Contains 39 genes, including prognostic typing and target drug

      Suitable Patient Profile:

      Patients with medulloblastoma

    • Whole Exome Sequencing

      Overview:

      The most complete detection products at present

      Product Features:

      Contains more than 21,000 human genes

      Suitable Patient Profile:

      Patients who want to fully understand the disease situation and  patients seeking medical treatment abroad

  • Assessment Process
    • Assessment Process
      Overview:
      Product Features:
      Suitable Patient Profile:
COPYRIGHT © 2020-2023泛生子. ALL RIGHTS RESERVED
Genetron Health Genetron Health Management
COPYRIGHT © 2020-2023泛生子. ALL RIGHTS RESERVED
Messages
  • *To
  • *Subject
  • *Name
  • *Tel
  • Work Unit
  • *Email
  • 详细说明:
  • Check code:
Genetron Health Genetron Health Management